MENU
IMTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immatics (IMTX) Ownership - Who owns Immatics?
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more
Profile
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
706.21M
P/E Ratio
29.35
Total Cash
490.52M
Projected Growth
N/A
Total Debt
16.02M
Revenue
115.5M
Risk (Beta)
0.92
Dividend Yield
N/A
Total Cash/Share
4.04
Total Debt/Equity
N/A
Revenue/Share
1.47 USD as % of share price
Fundamentals
IMTX
Capitalization
706M
P/E Ratio
29.35
Risk (Beta)
0.92
Dividend Yield
N/A
Total Cash
491M
Total Cash/Share
4.04
Total Debt
16M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.47%
Revenue
116M
ROE
N/A
Book Value
383M
P/B Ratio
1.16
Cash Flow
N/A
Earnings
-0.59
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
1.03M
Current Ratio
3.98
Current Revenue Per Employee
147402.33
Dividends Per Share - Security
N/A
EBITDA
-36.26M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-11.83
Shares Held By Institutions
816M
Shares Outstanding - Current
122M
Total Liabilities
195M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-27.707
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com